14 December 2022

Safety alerts for pharmaceutical products and medical devices

Reference: CIR-2022-00000247

To all Health facilities / all health care practitioners in Dubai's private health sector

Referring to the above subject, DHA notifies all health facilities regarding the circular issued by the MOHAP for perusal and adhere to what is stated

 

Drug Safety Communication- Prolia (denosumab)- Risk of Severe Hypocalcemia in Patients on Dialysis Prolia (denosumab)

Lifting the Recall of pharmaceutical product Antrolin Cream

Field Safety Notice Prefilled Glass Syringes and Certain Luer-Activated Valve (LAV) Connectors

Medical Device Recall WatchCare Incontinence Management System (IMS)

 

 

Thanks in advance for your good co-operation

 

Drug Control Section

Health Regulation Sector

DHA

 

Supporting Documents:

تعميم اداري 8973-2022 تحذير Prolia.pdf:

View Document

تعميم اداري 8974-2022-رفع سحب منتج طبي - Antrolin Cream-9066.pdf:

View Document

تقارير السلامة للوسائل الطبية - Prefilled Glass Syringes-9067.pdf:

View Document

تقارير السلامة للوسائل الطبية - WatchCare Incontinice Managment System-9069.pdf:

View Document